Key Highlights

  • Diluted EPS of USD 0.47 topped the consensus estimate of USD 0.46, while adjusted EPS reached USD 0.61.
  • Revenue rose 15% to USD 287.5 million, above the consensus estimate of USD 283.31 million.
  • Advanced Solutions sales jumped 33% to USD 48.0 million, while Industrial Solutions grew 12% to USD 239.5 million.
  • Fourth quarter guidance calls for Revenue of USD 265 to 295 million and adjusted EPS of USD 0.30 to 0.60.

IPG Photonics Corporation (NASDAQ:IPGP) reported third quarter 2026 revenue of USD 287.5 million, up 15% from USD 250.8 million a year earlier and above a consensus estimate of USD 283.31 million. Diluted EPS of USD 0.47 compared with USD 0.18 in the prior year quarter and with a consensus estimate of USD 0.46. Adjusted EPS, a non-GAAP measure, was USD 0.61 against USD 0.35. Net Income rose to USD 20.3 million from USD 7.5 million, and foreign exchange added about 1% to revenue growth.

Margins and Regional Mix

Gross Margin widened to 40.7% from 39.5%, with adjusted gross margin at 41.0%, helped by lower product costs and USD 5.0 million of net Tariff refunds, partly offset by lower Fixed Cost absorption. Operating Income more than doubled to USD 20.8 million from USD 7.9 million, lifting the Operating Margin to 7.2% from 3.1%, while adjusted EBITDA climbed 39% to USD 51.5 million from USD 37.0 million. Industrial Solutions, 83% of revenue, was led by welding and additive manufacturing, and Advanced Solutions gained on semiconductor and defense sales. By region, sales rose 14% in Asia and 33% in North America and fell 1% in Europe. Emerging growth products made up 52% of revenue, down from 58% in the prior quarter because of product mix. Chief Executive Officer Mark Gitin noted a fourth straight quarter of double digit revenue growth, with revenue above the midpoint of guidance.

Fourth Quarter Guidance and the Lumibird Deal

For the fourth quarter the company guided revenue to USD 265 to 295 million, adjusted gross margin to 37.0% to 40.0%, adjusted operating expenses to USD 91 to 94 million, adjusted EPS to USD 0.30 to 0.60 and adjusted EBITDA to USD 33 to 50 million. The guidance includes no contribution from the pending Acquisition of Lumibird Medical, which is scheduled to close in the fourth quarter and which management said would add revenue in Advanced Solutions. The company noted that trade policy and tariff uncertainty raise the risks around this outlook. Third quarter book-to-bill was approximately one.

Fourth Quarter Guidance Against Third Quarter Actuals

The midpoint of fourth quarter revenue guidance, USD 280 million, compares with USD 287.5 million in the third quarter, and the adjusted EPS range of USD 0.30 to 0.60 compares with USD 0.61. The adjusted gross margin range of 37.0% to 40.0% sits against 41.0% in the third quarter, a quarter that included USD 5.0 million of tariff refunds. Adjusted EBITDA guidance of USD 33 to 50 million compares with USD 51.5 million. Cash and cash equivalents were USD 710.7 million against USD 403.8 million at year end, while short term investments fell to USD 215.3 million from USD 435.5 million. Nine month Operating Cash Flow was USD 78.5 million versus USD 46.5 million.